FIGO Classification of Uterine Fibroids
The FIGO classification system categorizes uterine fibroids (myomas) into 9 types (0-8) based on their relationship to the endometrium, myometrium, and uterine serosa, with specific management strategies tailored to each type and patient fertility goals 1.
FIGO Classification System
The FIGO system divides fibroids into three main anatomical categories:
Submucosal Fibroids (Types 0-2)
- Type 0: Pedunculated intracavitary - entirely within the uterine cavity, attached by a stalk
- Type 1: <50% intramural extension - majority projects into the cavity
- Type 2: ≥50% intramural extension - majority within the myometrium but distorts the endometrial cavity
Intramural Fibroids (Types 3-4)
- Type 3: Contacts endometrium, 100% intramural - completely within the myometrium but touches the endometrial lining (this is the "hybrid" fibroid that was reclassified from intramural to submucosal) 2
- Type 4: Entirely intramural - no contact with endometrium or serosa
Subserosal Fibroids (Types 5-7)
- Type 5: Subserosal, ≥50% intramural - majority within myometrium
- Type 6: Subserosal, <50% intramural - majority projects outward
- Type 7: Pedunculated subserosal - attached to uterus by a stalk
Other
- Type 8: Other locations (cervical, parasitic, broad ligament)
Note: Fibroids can have hybrid classifications (e.g., Type 2-5) when they span multiple anatomical zones 1.
Management by FIGO Type and Clinical Context
For Submucosal Fibroids (Types 0-2)
Hysteroscopic myomectomy is the procedure of choice for pedunculated submucosal fibroids <5 cm (Type 0-1), offering equivalent quality of life improvement to more invasive approaches with shorter hospitalization and faster recovery 3.
Management Algorithm:
- First-line: Trial medical management (NSAIDs, combined oral contraceptives, tranexamic acid) 3
- Second-line: GnRH antagonists (elagolix, linzagolix, relugolix) with add-back therapy for preoperative size reduction 3
- Definitive: Hysteroscopic myomectomy for symptomatic patients with heavy uterine bleeding 3
Critical caveat: Type 3 fibroids represent a unique challenge - they are now classified as submucosal despite being 100% intramural. Hysteroscopic myomectomy appears feasible but data are extremely limited, with only 56 patients reported across three studies 4. These patients may require additional procedures (5.4% needed repeat intervention) and have higher synechiae rates 4.
For Intramural/Subserosal Fibroids (Types 3-7)
Reproductive Age WITH Fertility Desires
Laparoscopic or open myomectomy is usually appropriate, with medical management trialed first in most cases 3.
Treatment hierarchy:
- Medical management: GnRH antagonists with add-back therapy (FDA-approved for fibroid-related heavy menstrual bleeding) 3
- Laparoscopic myomectomy: Preferred for smaller/fewer fibroids - shorter hospital stays, faster recovery 3
- Open myomectomy: For multiple fibroids or very large uteri 3
- UAE: Controversial but may be appropriate - spontaneous pregnancy rates of 29.5% at 1 year and 40.1% at 2 years post-procedure, with 81% live birth rate 3
- MRgFUS: Limited evidence, insufficient data for fertility outcomes 3
Important counseling point: Pregnancy is possible after all uterus-preserving procedures, even when fertility preservation is not the primary goal 3.
Reproductive Age WITHOUT Fertility Desires
Multiple equivalent options exist: laparoscopic/open myomectomy, medical management, MRgFUS, or UAE - all are usually appropriate, with medical management trialed first 3.
Selection factors:
Medical management: For patients preferring non-invasive approach
UAE: 94% short-term symptom improvement, 85% long-term improvement, 7% eventual hysterectomy rate 3
MRgFUS: Rare complications (skin burns, nerve damage), good symptom improvement 3
Myomectomy: Improved quality of life up to 10 years 3
With Concurrent Adenomyosis
Medical management or UAE is usually appropriate, with medical management trialed first 3.
UAE demonstrates particular efficacy in this population: 94% short-term and 85% long-term symptom improvement, though 18% eventually require hysterectomy for persistent symptoms 3. The ongoing QUESTA trial will provide definitive comparison data between UAE and hysterectomy 3.
Postmenopausal Patients
Hysterectomy is usually appropriate as the next step for symptomatic postmenopausal patients with negative endometrial evaluation 3.
Hysterectomy provides definitive resolution of all fibroid-related symptoms and remains the most common treatment (75% of fibroid treatment in the United States) 3.
Key Clinical Pitfalls
Type 3 fibroids: Newly reclassified as submucosal but behave as "hybrid" lesions. Evidence for hysteroscopic management is extremely limited - only 56 patients in the literature 4. Consider this a gray zone requiring individualized surgical planning.
Fertility counseling: All patients undergoing uterus-preserving procedures must be counseled that pregnancy is possible, regardless of stated fertility desires 3.
Medical management limitations: GnRH agonists/antagonists suppress fertility during treatment and symptoms rapidly recur after cessation 3.
Ulipristal acetate: Despite efficacy data, hepatotoxicity concerns prevent FDA approval in the United States 3.
Imaging requirements: MRI is superior to ultrasound for accurate FIGO classification, particularly when fibroids are numerous, and is essential for surgical planning 5, 6, 1.